FIDELITY DISRUPTIVE MEDICINE ETF (FMED)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
FIDELITY DISRUPTIVE MEDICINE ETF (FMED) with AI Score 44/100 (Weak). FIDELITY DISRUPTIVE MEDICINE ETF (FMED) focuses on investing in companies revolutionizing medical diagnostics, therapies, and services. Market cap: 0, Sector: Financial services.
Last analyzed: Mar 17, 2026FIDELITY DISRUPTIVE MEDICINE ETF (FMED) Financial Services Profile
FIDELITY DISRUPTIVE MEDICINE ETF (FMED) is a niche asset management fund targeting companies transforming the healthcare sector through innovative medical technologies and services. With a focus on disruptive medicine, FMED offers investors exposure to high-growth areas like gene therapy, robotic surgery, and digital health, distinguishing it from broader healthcare ETFs.
Investment Thesis
FMED presents a focused investment opportunity within the high-growth area of disruptive medicine. The fund's concentration on companies transforming medical diagnostics, therapies, and services offers targeted exposure to innovative technologies like gene therapy, robotic surgery, and digital health. With a beta of 1.10, FMED exhibits slightly higher volatility compared to the broader market, potentially offering enhanced returns during periods of strong growth in the healthcare technology sector. Key catalysts include continued advancements in gene editing technologies, increasing adoption of robotic surgery, and the expansion of digital health platforms. These trends are expected to drive revenue growth for companies within FMED's portfolio. However, potential risks include regulatory hurdles, clinical trial failures, and competitive pressures from established healthcare companies. While FMED does not offer a dividend yield, its focus on capital appreciation through disruptive innovation makes it an interesting option for growth-oriented investors.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.06B indicates a small-cap ETF focused on niche disruptive medicine companies.
- Beta of 1.10 suggests slightly higher volatility compared to the broader market.
- Focused investment strategy targeting companies transforming medical diagnostics, therapies, and services.
- Exposure to high-growth areas like gene therapy, robotic surgery, and digital health platforms.
- No dividend yield, indicating a focus on capital appreciation rather than income.
Competitors & Peers
Strengths
- Focus on high-growth disruptive medicine sector.
- Potential for significant capital appreciation.
- Diversification within the disruptive medicine space.
- Expertise in identifying innovative healthcare companies.
Weaknesses
- Small market capitalization ($0.06B).
- Higher volatility compared to broader market (beta of 1.10).
- Concentrated investment strategy.
- Dependence on the success of disruptive technologies.
Catalysts
- Ongoing: Advancements in gene editing technologies driving growth in gene therapy companies.
- Ongoing: Increasing adoption of robotic surgery leading to higher demand for surgical robots.
- Ongoing: Expansion of digital health platforms improving access to healthcare services.
- Upcoming: Potential FDA approvals for novel gene therapies in the next 1-2 years.
- Upcoming: New product launches in the robotic surgery market in the next year.
Risks
- Potential: Regulatory hurdles and clinical trial failures delaying commercialization of new therapies.
- Potential: Competitive pressures from established healthcare companies limiting market share.
- Potential: Technological obsolescence rendering existing technologies obsolete.
- Ongoing: Economic downturn impacting healthcare spending and investment.
- Ongoing: Ethical concerns surrounding gene editing technologies.
Growth Opportunities
- Advancements in Gene Therapy: The gene therapy market is projected to reach $25 billion by 2030, driven by breakthroughs in gene editing technologies like CRISPR-Cas9. FMED can capitalize on this growth by investing in companies developing novel gene therapies for various diseases. The timeline for commercialization varies depending on the specific therapy and regulatory approvals, but several gene therapies are expected to reach the market in the next 3-5 years.
- Expansion of Robotic Surgery: The robotic surgery market is expected to grow to $18 billion by 2028, fueled by increasing adoption of minimally invasive surgical techniques. FMED can benefit from this trend by investing in companies that develop and manufacture surgical robots and related technologies. The competitive advantage lies in the precision and efficiency offered by robotic surgery, leading to improved patient outcomes and reduced hospital stays.
- Growth of Digital Health Platforms: The digital health market is projected to reach $660 billion by 2028, driven by increasing adoption of telehealth, remote patient monitoring, and mobile health apps. FMED can capitalize on this growth by investing in companies that develop and operate digital health platforms. The competitive advantage lies in the convenience and accessibility of digital health solutions, enabling patients to manage their health from anywhere.
- Increasing Adoption of AI in Healthcare: Artificial intelligence (AI) is transforming healthcare by improving diagnostics, treatment planning, and drug discovery. FMED can benefit from this trend by investing in companies that develop and implement AI-powered healthcare solutions. The market for AI in healthcare is expected to reach $45 billion by 2027, driven by the increasing availability of healthcare data and the development of sophisticated AI algorithms.
- Personalized Medicine: Personalized medicine, which tailors medical treatment to individual patient characteristics, is gaining traction. FMED can capitalize on this trend by investing in companies that develop personalized medicine solutions, such as genetic testing and targeted therapies. The market for personalized medicine is expected to reach $3.2 trillion by 2025, driven by advancements in genomics and proteomics.
Opportunities
- Growth in gene therapy, robotic surgery, and digital health markets.
- Increasing adoption of AI in healthcare.
- Expansion of personalized medicine.
- Potential for partnerships with established healthcare companies.
Threats
- Regulatory hurdles and clinical trial failures.
- Competitive pressures from established healthcare companies.
- Technological obsolescence.
- Economic downturn impacting healthcare spending.
Competitive Advantages
- Focus on a specific niche within the healthcare sector (disruptive medicine).
- Expertise in identifying and evaluating innovative healthcare companies.
- Potential for high growth due to exposure to disruptive technologies.
- Diversification within the disruptive medicine space.
About FMED
FIDELITY DISRUPTIVE MEDICINE ETF (FMED) is designed to provide investors with targeted exposure to companies at the forefront of medical innovation. The fund invests in businesses that are actively transforming medical diagnostics, therapies, and services, encompassing a range of cutting-edge fields such as gene therapy, robotic surgery, and digital health platforms. FMED aims to capture the growth potential of companies that are disrupting traditional healthcare models through technological advancements. The ETF's investment strategy focuses on identifying companies that are pioneering new approaches to healthcare delivery and treatment. This includes companies developing novel diagnostic tools, advanced surgical techniques, and innovative digital health solutions. By concentrating on disruptive technologies, FMED seeks to outperform broader healthcare indices and provide investors with access to high-growth opportunities within the healthcare sector. FMED's portfolio construction involves a rigorous selection process to identify companies with strong growth prospects and disruptive potential. The fund's managers conduct in-depth research to assess the technological capabilities, market opportunities, and competitive positioning of potential investments. This process helps to ensure that FMED's portfolio is composed of companies that are well-positioned to capitalize on the evolving healthcare landscape. As of 2026, FMED continues to focus on identifying and investing in companies that are shaping the future of medicine.
What They Do
- Invests in companies transforming medical diagnostics.
- Targets companies developing innovative therapies.
- Focuses on advancements in gene therapy.
- Includes companies involved in robotic surgery.
- Invests in digital health platforms.
- Seeks to capture growth potential in disruptive medicine.
Business Model
- Invests in publicly traded companies.
- Generates revenue through management fees.
- Aims to provide capital appreciation for investors.
- Rebalances portfolio to maintain focus on disruptive medicine.
Industry Context
The asset management industry is undergoing significant transformation, driven by technological innovation, changing investor preferences, and increasing regulatory scrutiny. ETFs like FMED are gaining popularity as investors seek targeted exposure to specific sectors and investment themes. The healthcare sector, in particular, is experiencing rapid innovation, with disruptive technologies like gene therapy, robotic surgery, and digital health platforms transforming traditional healthcare models. FMED is positioned to capitalize on these trends by investing in companies that are at the forefront of medical innovation. Competitors include AGGA, CNXT, FDFF, JANT, and PRXG, each offering different approaches to healthcare investing.
Key Customers
- Retail investors seeking exposure to healthcare innovation.
- Institutional investors looking for targeted healthcare investments.
- Financial advisors seeking diversified investment options.
- High-net-worth individuals interested in disruptive technologies.
Financials
Chart & Info
FIDELITY DISRUPTIVE MEDICINE ETF (FMED) stock price: Price data unavailable
Latest News
No recent news available for FMED.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FMED.
Price Targets
Wall Street price target analysis for FMED.
MoonshotScore
What does this score mean?
The MoonshotScore rates FMED's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Common Questions About FMED
What does FIDELITY DISRUPTIVE MEDICINE ETF do?
FIDELITY DISRUPTIVE MEDICINE ETF (FMED) is an exchange-traded fund that invests in companies at the forefront of medical innovation. The fund targets businesses that are actively transforming medical diagnostics, therapies, and services, encompassing a range of cutting-edge fields such as gene therapy, robotic surgery, and digital health platforms. FMED aims to provide investors with targeted exposure to the high-growth potential of disruptive technologies within the healthcare sector, differentiating itself from broader healthcare ETFs through its concentrated focus.
What do analysts say about FMED stock?
AI analysis is currently pending for FMED, therefore an analyst consensus is unavailable at this time. Generally, ETFs focused on disruptive technologies may be viewed as higher-risk, higher-reward investments. Key valuation metrics would include the growth rates of the underlying companies and the overall market sentiment towards innovative healthcare solutions. Investors should carefully consider their risk tolerance and investment objectives before investing in FMED, given its concentrated focus and potential volatility.
What are the main risks for FMED?
The main risks for FMED include regulatory hurdles, clinical trial failures, and competitive pressures from established healthcare companies. Companies developing new medical technologies often face lengthy and uncertain regulatory approval processes, which can delay or prevent commercialization. Clinical trial failures can also significantly impact the value of companies within FMED's portfolio. Additionally, established healthcare companies may have greater resources and expertise, posing a competitive challenge to smaller, innovative companies. Economic downturns can also impact healthcare spending and investment, affecting the performance of FMED.
What are the key factors to evaluate for FMED?
FIDELITY DISRUPTIVE MEDICINE ETF (FMED) currently holds an AI score of 44/100, indicating low score. Key strength: Focus on high-growth disruptive medicine sector.. Primary risk to monitor: Potential: Regulatory hurdles and clinical trial failures delaying commercialization of new therapies.. This is not financial advice.
How frequently does FMED data refresh on this page?
FMED prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven FMED's recent stock price performance?
Recent price movement in FIDELITY DISRUPTIVE MEDICINE ETF (FMED) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on high-growth disruptive medicine sector.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider FMED overvalued or undervalued right now?
Determining whether FIDELITY DISRUPTIVE MEDICINE ETF (FMED) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying FMED?
Before investing in FIDELITY DISRUPTIVE MEDICINE ETF (FMED), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending, limiting the availability of analyst consensus and valuation metrics.
- The disruptive medicine sector is subject to rapid technological change and regulatory uncertainty.